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Abstract
Background: Acarbose slows down the intestinal absorption of carbohydrates, but its effects on the secretion of
incretins are still poorly known. This study aimed to examine the effects of single-dose acarbose on the secretion of
incretins in patients with newly diagnosed type 2 diabetes mellitus (T2DM).
Methods: In this pilot study, twenty-three patients diagnosed with T2DM were randomly assigned to the oral
glucose tolerance test (OGTT) group (n = 11) and the mixed meal test (MMT) group (n = 12). Fourteen subjects with
normal OGTT were included as controls. Plasma glucose, insulin, glucagon, glucagon-like peptide-1 (GLP-1), and
glucose-dependent insulinotropic peptide (GIP) were measured at 0 (fasting), 15, 30, 60, 90, and 120 min after
nutrient load. A week later, controls underwent MMT, the OGTT group underwent OGTT receiving 100 mg
acarbose, and the MMT group underwent MMT receiving 100 mg acarbose. The same blood markers were
measured again.
Results: No significant difference was observed in the OGTT group before and after administering acarbose. In the
MMT group, postprandial levels of glucose (P < 0.01), insulin (P < 0.01), glucagon at 15 min (P < 0.05), glucagon area
under the curve (AUC) (P < 0.05), GIP levels at 30 min (P < 0.05), and GIP AUC (P < 0.05) were decreased after
receiving acarbose with a mixed meal, but GLP-1 levels and GLP-1 AUC did not change.
Conclusions: Single-dose acarbose could reduce the secretion of GIP and glucagon after a mixed meal in patients
with newly diagnosed T2DM. The influence of acarbose on incretin levels could be related to the types of
carbohydrate being consumed.
Trial registration: This study was registered with the Chinese Clinical Trial Registry (Registration Number:
ChiCTR-TRC-14004260, Date of Registration: 2014-01-19).
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Background
Considerable evidence suggests that incretin dysfunction
accompanies the development of type 2 diabetes mellitus
(T2DM). Incretins are estimated to account for approxi-
mately 50–70 % of the total insulin secreted after oral
glucose administration [1–3]. The most important incre-
tins are glucagon-like peptide-1 (GLP-1) and glucose-
dependent insulinotropic peptide (GIP). GLP-1 is secreted
from intestinal L cells when triggered by ingested nutri-
ents, while GIP is released from intestinal K cells. Studies
have demonstrated that an impaired secretion of incretins
in patients with T2DM is characterized by a decreased se-
cretion of GLP-1 after a mixed meal, resulting in the dys-
function of insulinotropic actions, or a total loss of GIP
effect even with normal levels [4]. However, many factors
may affect incretin secretion including meal composition,
obesity, insulin resistance, glucose intolerance, gastric-
emptying, and glucose-lowering drugs [5], and their exact
relationships are still poorly known.
Acarbose, an α-glucosidase inhibitor, is a polysac-
charide that could be used as a hypoglycemic drug
since it slows down the intestinal absorption of carbo-
hydrates [6]. Acarbose binds to the α-glycosidase and
thus inhibits food polysaccharides or disaccharides
from being decomposed into monosaccharide and sub-
sequently absorbed into the bloodstream [6]. There-
fore, acarbose can decrease postprandial blood glucose
from increasing through decreased intestinal absorp-
tion [6]. Since acarbose do not bind covalently to α-
glycosidase but competitively, it has to be consumed at
the same time as the meals. Acarbose is seldom
absorbed into the bloodstream (<5 %), and there is no
pharmacokinetic issues such as effective drug concen-
tration in the blood. Acarbose is excreted through the
feces [6]. Studies have shown increased postprandial
levels of GLP-1 in normal subjects receiving acarbose
[7, 8], but this effect was not observed in patients with
T2DM [9]. A previous study suggested that a 24-week
treatment with acarbose could stimulate the secretion
of GLP-1 [10]. However, it was difficult to identify that
the effect on the incretins was due to the long-term
improvement of glucotoxicity or the intrinsic action of
acarbose.
There are profound differences in the dietary pat-
terns between the Chinese and Western populations
[11, 12], and these differences could confound the as-
sociations observed in Western populations when food
intake is involved. We hypothesized that acarbose af-
fected the secretion of incretins in patients with newly
diagnosed T2DM. Therefore, the present study aimed
to identify whether a single dose of acarbose had the
potential to affect incretin levels beyond its glycemic




In this pilot study, patients newly diagnosed with T2DM
and healthy volunteers recruited from the endocrinology
outpatient clinic of the Guangdong General Hospital
from January 2009 to June 2010.
For patients, the inclusion criteria were: 1) newly di-
agnosed T2DM within 3 months according to the
WHO diabetes diagnostic criteria of 1999 [13]; (2)
aged 30–70 years; and (3) fasting plasma glucose
(FPG) >7 mmol/L and ≤9 mmol/L and/or 2-h plasma
glucose >11.1 and ≤16.6 mmol/L, HbA1c ≤9 %, and
body mass index (BMI) ≥18 kg/m2.
Fourteen subjects with normal oral glucose tolerance
test (OGTT) were included as controls. The inclusion
criteria for the control group were: 1) age 30–70 years;
and 2) OGTT FPG <5.6 mmol/L and 2-h plasma glu-
cose <7.8 mmol/L.
For all participants, exclusion criteria were: 1) treatment
with any antidiabetic drugs or drugs that affect insulin
sensitivity, plasma glucose, or carbohydrate metabolism
(glucocorticoids, diuretics, or beta-blocker); 2) history of
gastrointestinal disease or surgery; 3) history of gastrointes-
tinal disease or received treatment that affect gastroenteric
movement; 4) history of nephropathy, hepatopathy, or car-
diovascular disease; 5) history of diseases associated with
flatulence such as Roemheld syndrome, enterocele, intes-
tinal obstruction, or ulcer; 6) subjects having moderate to
severe renal or hepatic insufficiency (ALT >2.5-fold the
upper normal limit (ULN), and plasma creatinine >ULN);
or 7) pregnant women.
The study was approved by the local medical ethics
committee. All participants provided a written informed
consent. This study was registered with the Chinese
Clinical Trial Registry (ChiCTR-TRC-14004260, http://
www.chictr.org.cn).
Study design and intervention
Twenty-three patients newly diagnosed with T2DM and
meeting the inclusion criteria were randomly divided
into two groups using a random number table (Fig. 1):
the OGTT group and the mixed meal test (MMT)
group. The control and OGTT groups received 75 g of
anhydrous glucose orally, while the MMT group received
a mixed meal with a total calorie input of 370 kcal (car-
bohydrates 74 %, proteins 7 %, and fat 19 %). A week
later, the control group underwent MMT, and the other
two groups received 100 mg of acarbose orally (Glucobay®;
Bayer AG, Leverkusen, Germany) along with the same nu-
trient intake as the first time.
Laboratory measurements
Blood samples were collected in the morning after a 12-h
overnight fast. Samples were drawn into chilled tubes
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containing EDTA and aprotinin for the measurement of
plasma glucose, insulin, glucagon, and GIP at 0 (fasting),
15, 30, 60, 90, and 120 min after the nutrient load. Blood
samples for measuring GLP-1 were collected into chilled
tubes containing EDTA and DPP-4 inhibitor (Linco Cat#
DPP4, 10 μL of DPP-4 inhibitor per milliliter of blood)
within 30 s. After centrifugation, plasma samples were
kept at −70 °C until assayed.
Plasma GLP-1 (Cat No. GLP-1A-35HK, Linco Research,
Inc., St. Charles, MO, USA) [14, 15], GIP (Cat. No. RKC-
027-02, Phoenix Pharmaceuticals, Inc., Burlingame, CA,
USA) [16], and glucagon (Cat No. GL-32 k, Linco Re-
search, Inc., St. Charles, MO, USA) [17] were measured
using commercially available radioimmunoassay kits, ac-
cording to the manufacturers’ instructions. The intra-assay
coefficient of variation (CV) for GLP-1 was 21.2–30.3 %,
and the inter-assay CV was 12–43 %. The intra-assay CV
for GIP was <10 %, while the inter-assay CV was <15 %.
The intra-assay CV for glucagon was 4.0–6.8 % and the
inter-assay CV was 7.3–13.5 %.
Endpoints
The primary endpoint was the differences in the secre-
tion of incretins after a single dose of acarbose. The sec-
ondary endpoints included the effect of acarbose on
glucagon and the differences between newly diagnosed
patients with T2DM and healthy subjects in the secre-
tion of incretins and glucagon, and the changes in
plasma glucose and insulin after acarbose in T2DM.
Statistical analysis
Normally distributed continuous data are expressed as
mean ± standard deviation. Non-normally distributed
continuous data were log-transformed to normalize their
distribution. Data were compared using ANOVA and
the Tukey’s post hoc test. Differences in categorical vari-
ables were tested using the chi-square test. Statistical ana-
lysis was performed using SPSS 13.0 (SPSS, Inc., Chicago,
IL, USA). Two-sided P-values <0.05 were considered
significant.
Results
Characteristics of the participants
Twenty-three patients newly diagnosed with T2DM and
14 healthy volunteers were recruited (Fig. 1). The char-
acteristics of the participants are shown in Table 1. Sig-
nificant differences in age, BMI, and waist circumference
were observed between the controls and patients with
T2DM (P < 0.05). HbA1c, systolic blood pressure, total
cholesterol, and low-density lipoprotein cholesterol were
significantly higher in patients with T2DM than in
healthy controls (P < 0.05). There was no significant dif-
ference for all other characteristics between the two
groups (P > 0.05).
Plasma glucose, insulin, and glucagon before and after
acarbose
Before administering acarbose, plasma glucose in the
OGTT group was higher, and insulin levels at 15 min
(P < 0.01) and 30 min (P < 0.05) were lower than in the
control group after receiving an oral 75 g glucose load.
However, no difference was found in glucagon levels be-
tween the groups. When given a mixed meal, the MMT
Fig. 1 Study flowchart
Table 1 Characteristics of the participants
Characteristic Control group OGTT group MMT group
Number (male/female) 14 (7/7) 11 (5/6) 12 (9/3)
Age (year) 32.21 ± 3.13 54.45 ± 3.46* 56.75 ± 2.10*
BMI (kg/m2) 21.56 ± 0.63 25.02 ± 1.06* 25.52 ± 1.11*
WHR 0.81 ± 0.02 0.88 ± 0.02* 0.90 ± 0.02*
HBA1c (%) 5.6 ± 0.1 7.3 ± 0.4* 7.7 ± 0.4*
HBA1c (mmol/mL) 37 ± 1 56 ± 4* 61 ± 4*
SBP (mmHg) 112.21 ± 3.19 128.55 ± 3.18* 127.17 ± 4.43*
DBP (mmHg) 71.21 ± 2.64 78.45 ± 1.76* 74.33 ± 1.38
TC (mmol/L) 4.52 ± 0.17 5.60 ± 0.31* 5.39 ± 0.23*
TG (mmol/L) 0.88 ± 0.07 2.31 ± 0.58* 1.69 ± 0.40*
HDL-C (mmol/L) 1.38 ± 0.08 1.37 ± 0.12 1.40 ± 0.13
LDL-C (mmol/L) 2.07 ± 0.12 2.65 ± 0.16* 2.65 ± 0.22*
ALT (U/L) 23.17 ± 3.14 32.89 ± 7.55 26.00 ± 2.74
BUN (mmol/L) 4.38 ± 0.29 5.60 ± 0.38* 4.956 ± 0.39
Cr (μmol/L) 69.82 ± 6.40 78.22 ± 5.15 83.58 ± 4.69
Uric acid (μmol/L) 317.57 ± 15.13 353.25 ± 15.61 333.08 ± 17.57
BMI Body mass index, WHR waist-to-hip ratio, SBP systolic blood pressure,
DBP diastolic blood pressure, TC total cholesterol, TG triglyceride, HDL-C
high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol,
ALT alanine aminotransferase, BUN blood urea nitrogen, Cr creatinine
*P < 0.05 vs. controls
△P < 0.05 vs. the OGTT group
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group also presented high levels of plasma glucose and
low levels of insulin at 15 and 30 min (P < 0.05 vs. con-
trols), but glucagon levels in the MMT group at 30 and
90 min were increased compared with the control
group (P < 0.05) (Table 2).
Administering acarbose did not alter the levels of
plasma glucose, insulin, and glucagon in the OGTT
group at any time point, but plasma glucose was de-
creased in the MMT group after receiving acarbose.
Insulin levels were decreased significantly at 30, 60,
90, and 120 min after administering acarbose in the
MMT group, and glucagon was also decreased at
15 min (Table 2).
Levels of GLP-1 and GIP before and after administering
acarbose
Without acarbose, no difference was found in GLP-1
levels between the control and OGTT groups after the
75-g glucose load, but GIP levels were higher at 60 min
in the OGTT group compared with the control group
(P < 0.05). When given a mixed meal, the levels of GLP-
1 and GIP in the MMT group did not differ from the
control group (Table 2).
Acarbose did not induce any difference in the levels of
GLP-1 and GIP in the OGTT group. The levels of GLP-
1 in the MMT group did not change after single-dose
acarbose, but the GIP levels of the MMT group at
30 min were decreased significantly after acarbose
(Table 2).
Area under the curve of plasma glucose, insulin,
glucagon, GLP-1, and GIP before and after acarbose
Before acarbose, the area under the curve (AUC) of
plasma glucose in the OGTT group was markedly higher
than in the control group, but no difference was found
in the AUCs of insulin, glucagon, GLP-1, and GIP be-
tween the two groups. When given a mixed meal, the
AUCs of plasma glucose (P < 0.01) and glucagon (P < 0.05)
increased in the MMT group compared with the control
group, but the AUC of insulin was not different neither
were the AUCs of GLP-1 and GIP (Fig. 2).
Administering acarbose made no difference in the
AUCs of plasma glucose, insulin, glucagon, GLP-1, and
GIP in the OGTT group. The AUCs of plasma glucose,
insulin, and glucagon in the MMT group were signifi-
cantly different before and after administering acarbose
(P < 0.01), and so was the AUC of GIP (P < 0.05). How-
ever, the AUC of GLP-1 showed no difference with the
use of acarbose.
Discussion
The aim of the present study was to try to examine the
intrinsic effects of acarbose on the secretion of incretins
in drug-naive patients with newly diagnosed T2DM.
Results showed that no significant difference was ob-
served in the OGTT group before and after administer-
ing acarbose. In the MMT group, postprandial levels of
plasma glucose, insulin, glucagon at 15 min, glucagon
AUC, GIP levels at 30 min, and GIP AUC were de-
creased after receiving acarbose with a mixed meal, but
GLP-1 levels and GLP-1 AUC did not change. These re-
sults suggest that the influence of acarbose on incretin
levels is related to the types of carbohydrate being con-
sumed in patients with T2DM.
Inhibitors of α-glucosidase (such as acarbose) are
known to delay the intestinal hydrolysis of oligo- and di-
saccharides, mainly in the upper half of the small intes-
tine, by binding competitively and in a dose-dependent
manner to α-glucosidase, reducing their intestinal ab-
sorption, but acarbose has no direct effect on the ab-
sorption of glucose [18]. As a result, after taking 75 g
glucose, the OGTT group in this study did not present
significant changes in the levels of plasma glucose with
the administration of acarbose. Furthermore, the results
showed no difference in the levels of incretins and insu-
lin in the OGTT group after administering acarbose, in-
dicating that acarbose had no direct effect on the
secretion of incretins from L and K cells after the 75 g
glucose load.
In the present study, after acarbose, the MMT group
did not present significant difference in GLP-1, but the
levels at 30 min and the AUC of GIP were decreased sig-
nificantly. These findings are inconsistent with those of
other studies. Indeed, GLP-1 secretion is dependent on
both the size and the nutrient composition of the meal
[4]. Vilsboll et al. [19] demonstrated that the incretin re-
sponses were significantly higher in the group receiving
a large meal compared with those receiving a small meal
in lean patients with type 1 diabetes mellitus and obese
patients with T2DM (520 kcal vs. 260 kcal). Meal sizes
of 400–550 kcal have failed to demonstrate that acarbose
could enhance GLP-1 secretion [14, 20]. A previous
study has shown that miglitol, a first-generation α-
glucosidase inhibitor, induced an enhanced GLP-1 re-
lease with an ordinary meal of 720 kcal in obese women
with T2DM [21]. In another study using oral sucrose,
patients with poorly controlled T2DM also showed a
prolonged and enhanced secretion of GLP-1 after ad-
ministration of acarbose [22]. In the present study, the
meal size was 370 kcal and was designed to represent
the characteristic Chinese meal. It included 74 % carbo-
hydrates, 7 % protein, and 19 % fat [23, 24], which might
not be sufficient to stimulate the secretion of GLP-1
even with the administration of acarbose. However, fac-
tors such as the inclusion criteria of subjects (duration
of diabetes, severity of diabetes complications, combined
medications, and the degree of obesity and insulin resist-
ance) might influence incretin secretion. In the present
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Table 2 Comparison of plasma glucose, insulin, glucagon, GLP-1, and GIP before and after the administration of acarbose














0 min 4.77 ± 0.13 6.95 ± 0.56** 6.67 ± 0.51 4.73 ± 0.11 6.53 ± 0.36△△ 6.49 ± 0.30
15 min 7.29 ± 0.25 8.88 ± 0.59* 9.16 ± 0.57 6.46 ± 0.21# 7.69 ± 0.44△ 6.72 ± 0.31▲
30 min 8.47 ± 0.42 11.29 ± 0.60** 11.23 ± 0.66 7.59 ± 0.22 9.92 ± 0.47△△ 7.39 ± 0.47▲▲
60 min 7.74 ± 0.50 13.66 ± 0.83** 12.89 ± 0.78 6.62 ± 0.38 13.22 ± 0.66△△ 8.70 ± 0.48▲▲
90 min 6.17 ± 0.32 13.80 ± 0.95** 13.43 ± 1.03 5.17 ± 0.30 13.11 ± 0.87△△ 9.45 ± 0.61▲▲
120 min 5.58 ± 0.18 12.95 ± 1.06** 12.39 ± 1.16 5.36 ± 0.26 11.65 ± 1.03△△ 9.11 ± 0.72▲▲
Insulin (pmol/L)
0 min 44.96 ± 4.86 62.66 ± 9.27 63.15 ± 9.63 47.32 ± 7.43 61.73 ± 10.03 40.08 ± 18.76
15 min 437.26 ± 70.09 196.51 ± 70.16** 194.43 ± 41.90 419.56 ± 114.74 118.39 ± 14.66△△ 102.41 ± 24.43
30 min 586.97 ± 65.15 330.84 ± 76.93* 254.87 ± 41.78 566.20 ± 114.52 213.46 ± 50.03△△ 128.99 ± 28.18▲▲
60 min 646.02 ± 136.59 448.28 ± 72.11 395.81 ± 45.47 497.23 ± 123.59 321.36 ± 71.54 178.20 ± 43.16▲▲
90 min 492.54 ± 91.56 563.69 ± 95.32 501.14 ± 65.87 377.62 ± 104.38 387.32 ± 79.81 229.93 ± 67.12▲▲
120 min 288.95 ± 47.35 453.19 ± 63.14 480.14 ± 72.53 248.76 ± 83.14 353.76 ± 65.63△ 196.95 ± 48.54▲▲
Glucagon (pmol/L)
0 min 70.24 ± 5.94 74.92 ± 8.21 70.05 ± 6.58 74.24 ± 4.83 80.54 ± 5.77 61.62 ± 6.18▲▲
15 min 75.72 ± 8.68 78.52 ± 8.37 81.32 ± 11.82 92.13 ± 7.47 99.40 ± 8.40 77.88 ± 9.07▲
30 min 69.41 ± 6.97 83.81 ± 6.48 70.83 ± 5.63 70.82 ± 4.35 94.35 ± 8.82△ 88.34 ± 8.28
60 min 69.46 ± 7.10 63.09 ± 5.39 61.28 ± 7.00 62.31 ± 3.87 79.23 ± 7.47 77.06 ± 6.41
90 min 59.01 ± 5.61 64.00 ± 8.29 51.41 ± 6.32 63.80 ± 3.72 82.20 ± 8.10△ 73.31 ± 9.72
120 min 59.81 ± 4.24 58.38 ± 6.90 55.25 ± 6.33 74.24 ± 4.83 63.20 ± 4.34 60.14 ± 7.74
GLP-1 (pmol/L)
0 min 37.02 ± 3.95 36.46 ± 4.84 44.53 ± 6.73 35.90 ± 3.08 30.54 ± 4.71 41.87 ± 6.80
15 min 39.79 ± 5.79 33.51 ± 5.76 42.29 ± 5.62 35.85 ± 4.49 43.90 ± 6.58 36.43 ± 7.72
30 min 29.89 ± 3.04 32.93 ± 6.06 35.29 ± 4.22 33.66 ± 3.91 37.48 ± 5.21 35.44 ± 5.83
60 min 33.18 ± 3.72 35.19 ± 4.78 35.82 ± 6.88 30.20 ± 4.09 35.44 ± 4.80 43.42 ± 6.58
90 min 29.34 ± 3.17 37.05 ± 5.60 39.81 ± 7.89 28.45 ± 3.07 39.12 ± 5.01 35.33 ± 4.98
120 min 31.20 ± 5.17 30.73 ± 4.22 29.42 ± 5.20 31.51 ± 3.37 41.48 ± 5.74 32.58 ± 5.43
GIP (pmol/L)
0 min 31.85 ± 3.61 31.94 ± 12.18 43.53 ± 13.96 37.33 ± 5.93 34.36 ± 3.67 33.86 ± 8.82
15 min 46.19 ± 4.97 82.50 ± 26.80 55.12 ± 13.82 78.87 ± 15.89# 58.42 ± 19.96 31.27 ± 6.20
30 min 41.39 ± 5.89 52.65 ± 22.53 56.66 ± 17.46 68.23 ± 16.42 76.52 ± 16.98 41.99 ± 8.97▲
60 min 41.30 ± 4.87 76.49 ± 13.61* 72.78 ± 19.30 42.36 ± 8.21 78.95 ± 25.37 59.34 ± 13.92
90 min 50.07 ± 10.14 59.62 ± 18.67 94.76 ± 25.21 61.43 ± 14.92 88.63 ± 25.35 63.57 ± 18.41
120 min 52.23 ± 9.94 65.50 ± 21.84 57.68 ± 9.81 50.39 ± 8.80 72.86 ± 20.73 33.46 ± 4.32
*P < 0.05 OGTT group vs. controls before the administration of acarbose
**P < 0.01 OGTT group vs. controls before the administration of acarbose
#P < 0.05 P < 0.05 MTT vs. OGTT in conrols
△P < 0.05 MMT group vs. controls group before the administration of acarbose
△△P < 0.01 MMT group vs. controls before the administration of acarbose
▲P < 0.05 MMT group before and after the administration of acarbose
▲▲P < 0.01 MMT group before and after the administration of acarbose
§Before the administration of acarbose
☆: After the administration of acarbose
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study, patients were newly diagnosed with T2DM and
were slightly overweight (BMI of 25.5 ± 1.1 kg/m2), and
they had no history of antidiabetic drugs or chronic
complications of diabetes. Therefore, GLP-1 might not
yet be impaired severely in these patients. In addition,
subjects in this study received a single dose of acarbose,
which was different from other studies. Indeed, Zheng et
al. [10] reported that a 24-week treatment with acarbose
significantly increased the levels of GLP-1 in newly diag-
nosed T2DM patients. The β cells function and insulin
sensitivity can be improved by the elimination of gluco-
toxicity, which can affect the secretion of incretins dir-
ectly and indirectly [5]. Glycemic control after the 24-
week administration of acarbose may contribute in part
to the restoration of the GLP-1 secretion defect. How-
ever, no significant changes were found in GLP-1 levels
with the single dose of acarbose.
Recent studies of inhibitors of α-glucosidase (acarbose
and miglitol) in patients with T2DM have indicated that
these drugs can reduce the levels of GIP [20, 25, 26].
GIP is released from K cells in the duodenum, which
can be stimulated through the absorption of carbohy-
drates and fat [27]. Studies have shown that the secre-
tion of GIP increases significantly after the excessive
ingestion of nutrients, indicating that GIP plays an im-
portant role in the development of obesity and insulin
resistance induced by a high-calorie diet [28]. The
present study showed that the GIP and glucagon levels
decreased after a mixed meal in patients with new diag-
nosed T2DM by treatment with single dose acarbose.
It is known that the secretion and activation of incre-
tins are impaired in patients with T2DM [5], and this
dysfunction can be observed even in the early stage of
glucose metabolism disorders [29]. Incretin dysfunction
is not necessarily a characteristic unique to T2DM
because several studies reported no GLP-1 deficiency in
the early stage of abnormal glucose tolerance, suggesting
that incretin deficiency could be the consequence of
T2DM development [30, 31]. In addition, patients with
long duration of diabetes and poor response of glucagon
to glucose stimulation may present GLP-1 dysfunction
[5]. A previous study showed that acarbose decreased
GLP-1 levels in patients with T2DM [10]. In the present
study, subjects were newly diagnosed with diabetes and
had a mean HbA1c of 7.3 ± 0.4 % and a mean BMI of
about 25 kg/m2, which may explain why no difference
was found in GLP-1 levels between healthy subjects and
patients with T2DM. A possible explanation is the fact
that the effect of meals on GLP-1 secretion is negligible
in East Asians, as well as GLP-1 secretion after OGTT
[32]. Additional study is necessary to address this issue.
On the other hand, GIP levels were increased signifi-
cantly at 60 min during OGTT in patients with T2DM
compared with controls. The present study also showed
that insulin levels in the early phase were reduced while
GIP was relatively high, suggesting that the biological
action of GIP on stimulating glucose-dependent insulin
secretion was impaired. Such phenomenon was demon-
strated in a previous study of patients with T2DM, in
whom GIP levels were normal or increased but the insu-
linotropic response was diminished substantially [5]. As
for the present study, the differences in GIP between the
controls and patients with T2DM may suggest that the
early changes in T2DM development may occur earlier
than the changes in GLP-1 levels.
OGTT is a load of pure glucose. Since acarbose delays
the hydrolysis of polysaccharides and disaccharides but
has no effect on the direct absorption of glucose, acarbose
had no effect on the OGTT parameters [18]. On the other
hand, since the mixed meal contained polysaccharides and
Fig. 2 Effect of acarbose on an oral glucose tolerance test before and after acarbose administration in newly diagnosed patients with type 2
diabetes. a Area under the curve (AUC) for plasma glucose. b AUC for insulin levels. c AUC of glucagon. d AUC of GLP-1. e AUC of GIP
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disaccharides, acarbose delayed their hydrolysis, resulting
in changes in incretins. These results are supported by a
previous study that showed some effects of a single dose
acarbose after a meal tolerance test [33].
This study has several limitations. First, the number of
subjects was probably not sufficient to provide definitive
evidence of the effect of acarbose on incretins. Indeed,
the effects of acarbose on incretins may be subtle, lead-
ing to differences that cannot be detected using a small
sample size. In addition, variations in the methods used
to measure incretin levels may confound the detection
of differences, particularly with a small sample size. Sec-
ondly, the controls were not perfectly matched to the
patients. Finally, the generalisability of these results may
be limited by the particularities of the T2DM observed
in Chinese [32]. Indeed, T2DM in Chinese is character-
ized by a rapid increase in prevalence due to the West-
ernized lifestyle changes, as well as specific genetic
characteristics that result in low insulin secretory cap-
acity in East Asians [32]. Further study is still necessary
to determine adequately the effects of acarbose on the
metabolism of incretins.
Conclusions
A single dose of acarbose in drug-naive patients newly
diagnosed with T2DM was found to decrease GIP and
glucagon only in MMT rather than OGTT, indicating
that these hormones might be influenced by acarbose
through the delayed absorption of nutrients. The influence
of acarbose on incretin levels could be related to the types
of carbohydrate intake in patients with T2DM.
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